This post is from a suggested group
The Transformative Impact of Immunotherapy and Molecular Diagnostics on the Global Bladder Cancer Market Treatment Paradigm
The Bladder Cancer Market is undergoing a profound transformation, fueled by the rising global incidence of the disease (strongly correlated with smoking and occupational exposures) and the introduction of highly effective, novel treatment modalities, most notably Immunotherapy. While Transurethral Resection of Bladder Tumor (TURBT) remains the standard for initial diagnosis and treatment of non-muscle invasive bladder cancer (NMIBC), the market's trajectory is now dictated by advancements in systemic therapies for advanced and muscle-invasive disease (MIBC). The most significant driver is the clinical success and expanding use of Immune Checkpoint Inhibitors (ICIs), particularly those targeting the PD-1/PD-L1 pathway. These therapies harness the patient’s own immune system to attack cancer cells, offering significant improvements in overall survival and progression-free survival for patients who have progressed after platinum-based chemotherapy. Furthermore, the market for Intravesical Therapy, including Bacillus…
